Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

Published:2011-04-26 Issue:3 Volume:30 Page:1121-1131
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Lapusan Simona,Vidriales Maria B.,Thomas Xavier,de Botton Stephane,Vekhoff Anne,Tang Ruoping,Dumontet Charles,Morariu-Zamfir Rodica,Lambert John M.,Ozoux Marie-Laure,Poncelet Philippe,San Miguel Jesus F.,Legrand Ollivier,DeAngelo Daniel J.,Giles Francis J.,Marie Jean-Pierre

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-011-9670-0.pdf

Reference16 articles.

1. Shipley JL, Butera JN (2009) Acute myelogenous leukemia. Exp Hematol 37:649–58

2. Dombret H, Raffoux E, Gardin C (2008) Acute myeloid leukemia in the elderly. Semin Oncol 35:430–8

3. Advani AS, Hunger SP, Burnett AK (2009) Acute leukemia in adolescents and young adults. Semin Oncol 36(3):213–26

4. Kreitman RJ (2009) Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des 15:2652–64

5. Legrand O, Perrot JY, Baudard M et al (2000) The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 96(3):870–7

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window;Molecular Cancer Therapeutics;2024-04-01

2. Advanced Targeting Systems for Tissue-Specific Drug Delivery;Interdisciplinary Cancer Research;2024

3. Unlocking the Power of Immune Microenvironment in AML Therapy: Current Insight and Future Prospects;Interdisciplinary Cancer Research;2024

4. New insights into the anticancer therapeutic potential of maytansine and its derivatives;Biomedicine & Pharmacotherapy;2023-09

5. Exploration of the antibody–drug conjugate clinical landscape;mAbs;2023-08-28